Figure 2
Figure 2. Effects of MG-132 on NF-κB activation and MMP-3 secretion in bEnd.3 cells. NF-κB activation (A-D) or MMP-3 secretion (E-F) is shown on 6 hours of OGD followed by 18 hours of normoxia and t-PA treatment without or with addition of MG-132 (A,B,E,F) or anti-LRP antibody (C-D). Representative immunoblots against NF-κB and HDAC1 as an internal control (A,C) or pro–MMP-3 (E) are also shown. Quantitative data of NF-κB (B,D) and MMP-3 (F) are shown as fold increase and represent mean ± SD of 3 to 15 experiments. *P < .05; **P < .01; ***P < .001.

Effects of MG-132 on NF-κB activation and MMP-3 secretion in bEnd.3 cells. NF-κB activation (A-D) or MMP-3 secretion (E-F) is shown on 6 hours of OGD followed by 18 hours of normoxia and t-PA treatment without or with addition of MG-132 (A,B,E,F) or anti-LRP antibody (C-D). Representative immunoblots against NF-κB and HDAC1 as an internal control (A,C) or pro–MMP-3 (E) are also shown. Quantitative data of NF-κB (B,D) and MMP-3 (F) are shown as fold increase and represent mean ± SD of 3 to 15 experiments. *P < .05; **P < .01; ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal